Veradermics, Incorporated
MANE
$126.89
$7.526.30%
NYSE
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 508.79% | 371.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 131.22% | 285.38% | |||
| Operating Income | -131.22% | -285.38% | |||
| Income Before Tax | -119.61% | -285.99% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -119.61% | -285.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -119.61% | -285.99% | |||
| EBIT | -131.22% | -285.38% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 93.32% | -328.18% | |||
| Normalized Basic EPS | 92.87% | -279.38% | |||
| EPS Diluted | 93.32% | -328.18% | |||
| Normalized Diluted EPS | 92.87% | -279.38% | |||
| Average Basic Shares Outstanding | 2,981.03% | 1.75% | |||
| Average Diluted Shares Outstanding | 2,981.03% | 1.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||